ABVC BioPharma anticipates approximately $19 million in cash revenue this year through three major global licensing agreements and a strategic contract development and manufacturing organization acquisition. The company's first licensing agreement covers major depressive disorder and attention-deficit/hyperactivity disorder drug candidates, targeting a therapeutic market projected to reach $38 billion by 2032. The MDD therapeutics market is expected to hit $14 billion by 2027, while the ADHD market is forecast to surpass $24 billion by 2032, positioning ABVC to address growing demand for innovative treatments.
A second global licensing agreement involves Vitargus®, a biodegradable vitreous substitute for retinal detachment surgery. The ophthalmic medical device market is anticipated to grow to $120 billion by 2033, with over 1.8 million retinal detachment surgeries performed annually. This partnership allows ABVC to participate in an expanding market where Vitargus® offers potential improvements in post-surgical outcomes. The company's third partnership focuses on oncology, covering drug candidates targeting pancreatic cancer, non-small cell lung cancer, triple-negative breast cancer, and myelodysplastic syndromes. The global oncology drug market is expected to exceed $533 billion by 2028, growing at a 12.6% compound annual growth rate.
Complementing these licensing agreements, ABVC's $60 million CDMO acquisition enhances the company's vertical integration strategy. The facility provides cost-effective in-house manufacturing, enables revenue diversification through contract manufacturing services, and supports scalable commercial-scale production. The CDMO market itself is projected to reach $191 billion by 2029, creating additional revenue opportunities beyond the company's therapeutic pipeline. With a total addressable market exceeding $500 billion across its therapeutic areas, ABVC BioPharma demonstrates a comprehensive approach to long-term value creation and market expansion.
The company's strategy of leveraging global licensing agreements while maintaining manufacturing capabilities through the CDMO acquisition positions it to capture value across multiple high-growth segments of the biopharmaceutical industry. This integrated approach addresses both therapeutic development and production scalability, which could enhance ABVC's competitive position as markets for mental health treatments, ophthalmic devices, and oncology therapies continue to expand globally.
